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Abstract
Background: Anaemia is highly prevalent in children of developing countries. It is associated with
impaired physical growth and mental development. Palmar pallor is recommended at primary level
for diagnosing it, on the basis of few studies. The objective of the study was to systematically assess
the accuracy of clinical signs in the diagnosis of anaemia in children.
Methods: A systematic review on the accuracy of clinical signs of anaemia in children. We
performed an Internet search in various databases and an additional reference tracking. Studies had
to be on performance of clinical signs in the diagnosis of anaemia, using haemoglobin as the gold
standard. We calculated pooled diagnostic likelihood ratios (LR's) and odds ratios (DOR's) for each
clinical sign at different haemoglobin thresholds.
Results: Eleven articles met the inclusion criteria. Most studies were performed in Africa, in
children underfive. Chi-square test for proportions and Cochran Q for DOR's and for LR's showed
heterogeneity. Type of observer and haemoglobin technique influenced the results. Pooling was
done using the random effects model. Pooled DOR at haemoglobin <11 g/dL was 4.3 (95% CI 2.6–
7.2) for palmar pallor, 3.7 (2.3–5.9) for conjunctival pallor, and 3.4 (1.8–6.3) for nailbed pallor.
DOR's and LR's were slightly better for nailbed pallor at all other haemoglobin thresholds. The
accuracy did not vary substantially after excluding outliers.
Conclusion: This meta-analysis did not document a highly accurate clinical sign of anaemia. In view
of poor performance of clinical signs, universal iron supplementation may be an adequate control
strategy in high prevalence areas. Further well-designed studies are needed in settings other than
Africa. They should assess inter-observer variation, performance of combined clinical signs,
phenotypic differences, and different degrees of anaemia.
Background
The global prevalence of anaemia is estimated in 2 billion
people, that is, in about 30% of the worldwide popula-
tion[1]. An even larger number of people present iron
deficiency [1]. Every 9 of 10 persons affected of anaemia
live in developing countries [2]. Anaemia prevalence in
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Latin America is 46% in children [3], with differences
within countries. In Peru and Chile it is 50% and 8%,
respectively [4,5].
Anaemia is related to impaired physical growth and men-
tal development [6]. It is also associated to a higher risk of
infant and child mortality, particularly when it co-exists
with malnutrition and other risk factors [7].
It is therefore important to make a timely and accurate
diagnosis and initiate an early intervention to reduce the
negative impact of anaemia. The laboratory diagnosis of
anaemia through any of several techniques is not widely
available and its cost is often unaffordable in poor areas
of the world. This stimulated several studies to assess the
accuracy of clinical signs for screening of anaemia.
The Integrated Management of Childhood Illness (IMCI)
strategy developed by the World Health Organization rec-
ommends the use of palmar pallor as the initial screening
tool [8]. This recommendation is based mainly on the
interpretation of results of studies performed in the Gam-
bia [9], Kenya [10], and Malawi [11]. None of these stud-
ies showed in fact a clear superiority of palmar pallor.
Only the Kenya study showed that palmar pallor per-
formed better than conjunctival pallor when used by
health workers but not by study physicians [10]. One of
them used packed red cells volume as the gold standard
[9]. Packed red cells volume is a controversial gold stand-
ard for anaemia, as it varies with different physiologic and
pathologic conditions such as hydration status, and its
correlation with haemoglobin is not optimal [12].
Thus we were prompted to perform a systematic review to
assess the accuracy of clinical pallor in the diagnosis of
anaemia. The specific objective of the study was to answer
the question of whether there is a clinical sign that best
predicts the presence or absence of anaemia in children.
Table 1: Summary of primary studies characteristics
Author Year Country Location Ages Number Setting Pallor Haemoglobin cut-off 
assessed (g/dL)
Wurapa FK31 1986 Zambia Rural < 4 y 12 Outpatient C <11
Thaver IH32 1994 Pakistan Urban 6 m-5 y 947 Outpatient C,N,P,T <11
Luby SP11 1995 Malawi Rural < 6 y 1104 Outpatient C,N,P,T <11, <8, <5
Sdepanian VL33 1996 Brazil Urban 6 m-5 y 143 Outpatient C,G,N,P,T <11
Kalter HD34 1997 Bangladesh Urban 2 m-5 y 482 Emergency C,P <11, <8, <5
Zucker JR10 1997 Kenya NS 2 m-5 y 1666 Outpatient C,N,P,T <8, <5
NS 2 m-5 y 1048 Inpatient C,N,P,T <8, <5
Stoltzfus RJ35 1999 Tanzania Urban < 5 ya 613 Outpatient C,N,P <7,
Urban < 5 yb 537 Outpatient C,N,P <7
Urban > 5 y 3302 Outpatient C,N,P <7
Getaneh T36 2000 Ethiopia Urban 2 m-5 y 574 Outpatient C,N,P,T <11, <8, <7, <5
Muhe L37 2000 Ethiopia Rural 2 m-5 y 2540 Outpatient C,N,P,T <8, <5
Wamae CN38 2000 Kenya Rural 2–4 y 574 Outpatient P <11
Desai MR 29 2002 Kenya Rural < 5 y 3782 Outpatient C,G,N,P,T <7, <5
Observers Kappa Anaemia Prev. Malaria area Worm area Haemoglobin Technique Quality Score
Physicians No 16% NS NS Coulter 12
Physicians No 78% NS NS Hemocue 12
Health workers No 82% NS NS Spectrophotometer 13
Paediatricians/Res. No 41% NS NS Coulter 11
Paediatricians No 81% No NS Hemocue 11
Physicians No 59% NS NS Hemocue 12
Physicians No 91% NS NS Hemocue
Health workers No 81% NS Yes Hemocue 14
Health workers No 52% NS Yes Hemocue
Health workers No 32% NS Yes Hemocue
Nurses Yes 46% Yes Yes Hemocue 12
Physicians Yes 61% Yes Ns Hemocue 13
Health workers No 61% Yes Yes Spectrophotometer 12
Parents No 66% NS NS Hemocue 14
NS: Not stated, C: Conjunctiva, N: Nailbed, P: Palm, T: Tongue, G: General, Res.: residents, Prev.: prevalence. a and b are referred to cohorts 
studied in 1996 and 1997, respectively.BMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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The signs most frequently assessed in primary studies are
conjunctival, palmar and nailbed pallor. The review did
not include respiratory and cardiovascular signs as they
are unspecific for anaemia and are furthermore related to
severe anaemia with haemodynamic repercussion.
Methods
The review was aimed to include all studies performed in
children aged 0 through 18 years old fulfilling pre-estab-
lished inclusion criteria.
Inclusion criteria
1. Studies on individual or combined accuracy of conjunc-
tival, palmar or conjunctival pallor in the clinical diagno-
sis of anaemia.
2. Studies performed in children 0 through 18 years old.
3. Original articles. Review articles and letters to editors
were not considered, except when they had enough infor-
mation to assess the diagnostic performance of clinical
signs of anaemia.
Individual and pooled DOR's at Hb <11 g/dL Figure 1
Individual and pooled DOR's at Hb <11 g/dL.BMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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4. Prospective or retrospective studies performed in outpa-
tient or inpatient children.
5. Articles with enough information to assess the diagnos-
tic performance of clinical signs of anaemia, namely sen-
sitivity, specificity, likelihood ratios and predictive values.
6. Studies in which haemoglobin was used as the gold
standard.
Exclusion criteria
1. Studies not related to assessment of clinical signs in the
diagnosis of anaemia.
2. Studies with insufficient information for deriving the
diagnostic performance of clinical signs.
3. Studies in which it was not used a gold standard or
those in which haemoglobin was not the gold standard
Individual and pooled DOR's at Hb <8 g/dL Figure 2
Individual and pooled DOR's at Hb <8 g/dL.BMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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Search strategies
Two independent reviewers (JPC, CA) made an Internet
search of the literature. The databases searched were the
National Library of Medicine database from 1966 through
January, 2002 and EMBASE from 1986 through January,
2002. In addition we searched the American and Carib-
bean Health Sciences Literature (Literatura Americana y
del Caribe en Ciencias de la Salud, LILACS) database from
1986 through February, 2002 and the African Health
Anthology database from 1924 through July, 2002. This
search was combined with a manual tracking of articles
deemed relevant and found in the references section of
primary and qualitative review articles. Details of the key
words used are presented as an appendix [See Additional
File 1].
The abstracts of the primarily identified articles were read
by the same two independent reviewers to assess whether
they were related to the clinical diagnosis of anaemia.
Those deemed to be relevant were then retrieved and read
Individual and pooled DOR's at Hb <7 g/dL Figure 3
Individual and pooled DOR's at Hb <7 g/dL.BMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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as full papers. Any discrepancy between the reviewers was
solved by consensus.
Methodological quality of primary studies
We assessed the methodological quality of primary stud-
ies according to modified published recommendations
[13]. The quality score was derived by ascribing 2 points
for each of the major criteria related to systematic and
blind application of clinical signs and gold standard to all
patients, and 1 point for each of the remaining criteria.
The maximum possible score was 16 and the minimum
was 0. The final validity rating was reached by consensus.
The quality criteria details are presented as an appendix
[see Additional File 2].
Methods for calculating the diagnostic performance of 
index tests
Table 2 × 2 were reconstructed from the original data. Sen-
sitivity, specificity, predictive values, and likelihood ratios
with their corresponding 95% CIs were calculated for each
Individual and pooled DOR's at Hb <5 g/dL Figure 4
Individual and pooled DOR's at Hb <5 g/dL.BMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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primary study. Calculations were performed separately for
each clinical sign and by different haemoglobin thresh-
olds used in the primary studies. Whenever the 2 × 2
tables contained a 0 cell, 0.5 was added to all cells to avoid
undefined results.
The diagnostic odds ratio (DOR) of each primary study
was calculated according to the following formula [14]:
DOR = [Sensitivity/(1-sensitivity]/[(1-specificty)/specifi-
city]
The DOR represents the ratio of the odds of a positive test
result in subjects with the disease to the odds of a positive
test result in subjects without the disease. A DOR of 1
means that the test has no discriminative power. When
the DOR is more than one, the odds of a positive test
result are higher in the diseased group.
Methods of homogeneity assessment
Studies were analyzed separately for homogeneity of
results by clinical sign and by haemoglobin threshold
through chi-square test for proportions (sensitivity and
specificity), through Cochran Q for LR's and DOR's [15]
and through DOR graphic plotting of individual studies,
along with their 95% CI graphs [16].
Mathematical pooling
Pooled proportions (sensitivity and specificity) were cal-
culated through the weighted averages taking into account
the sample size of each study. Likewise, DOR's and LR's
were pooled. The Mantel-Haenszel fixed effects model
was planned to use if the studies were homogeneous for
the diagnostic performance indexes and the DerSimonian
Laird random effect model if they showed heterogeneity
[17]. The 95% CIs were also calculated for all the pooled
diagnostic indexes [16]. LR's and DOR's were recalculated
after outlier's exclusion.
Diagnostic performance and 95% CIs of individual stud-
ies, homogeneity assessment, mathematical pooling and
weighing were performed through the use of Metadisc
software version Beta 1.1.1 [18].
Exploration of heterogeneity
Potential sources of heterogeneity on diagnostic perform-
ance were assessed through Metaregression [18]. Pre-spec-
ified potential influential covariates included clinical
setting (outpatients or inpatients), continent of study
(Africa, Asia, Latin America), age group (children up to 5
years old, children older than 5 years old), technique of
haemoglobin measurement (Hemocue®, spectrophotom-
etry, Coulter®), whether or not the study setting was
endemic for malaria or for intestinal worms, type of
observer (physician, nurse, technician, parents), and
methodological quality score (continuous variable). For
each haemoglobin threshold category and for each test,
multivariate metaregression was run including the above
signaled covariates to assess whether any of them showed
a significant influence on lnDOR. The metaregression was
weighted by study size and the threshold effect was not
considered, as there were not additional cutoff points
within each pre-specified haemoglobin threshold.
Table 3: Pooled diagnostic performance markers at Hb <8 g/dL
Clinical 
Pallor
Total N Diseased Sensitivity 
(95% IC)
Specificity 
(95% IC)
Likelihood 
Ratio+(CI, 95%)
Likelihood 
Ratio-(CI, 95%)
DOR 
(CI, 95%)
AUC* 
SROC**
Conjunctiva 8867 2711 70.8(69–72.5) 69(67.8–70.1) 2.5(1.5–4.1) 0.4(0.3–0.7) 5.9(2.4–14.8) 0.7687
Palm 8998 2713 80.9(79.4–82.3) 67.7(66.5–68.8) 2.7(2.3–3.0) 0.3(0.2–0.4) 10.1(6.2–16.4) 0.8274
Nailbed 6841 2043 79.7(77.9–81.4) 71.2(69.9–72.4) 3.0(2.5–3.6) 0.3(0.1–0.5) 12.4(5.9–25.9) 0.8477
*AUC: area under the curve, **SROC: summary receiver operating characteristics curve.
Table 2: Pooled diagnostic performance markers at Hb <11 g/dL
Clinical 
Pallor
Total N Diseased Sensitivity 
(95% IC)
Specificity 
(95% IC)
Likelihood 
Ratio+(CI, 95%)
Likelihood 
Ratio-(CI, 95%)
DOR 
(CI, 95%)
AUC* 
SROC**
Conjunctiva 3195 2367 43.6(41.7–45.6) 81.4(78.6–83.9) 2.3(1.7–3.1) 0.7(0.5–0.9) 3.7(2.3–5.9) 0.7058
Palm 3885 2731 39.2(37.4–41.1) 86.7(84.6–88.5) 3.0(2.0–4.6) 0.7(0.6–0.8) 4.3(2.6–7.2) 0.7270
Nailbed 2534 1867 29.2(27.2–31.3) 88.5(85.8–90.7) 2.7(1.6–4.5) 0.8(0.7–0.9) 3.4(1.8–6.3) 0.6942
*AUC: area under the curve, **SROC: Summary receiver operating characteristics curve.BMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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Post-test probabilities of anaemia
To graphically illustrate the relative usefulness of each par-
ticular clinical sign of anaemia at each haemoglobin
threshold, different pre-test probability values were plot-
ted against post-test probability values for both positive
(LR+) and negative (LR-) results, before and after outlier's
exclusion. The post-test probability for a disorder is
another way to assess the value of a diagnostic test. It rep-
resents the chances that your patient has a disease. It
incorporates information about the disease prevalence,
the patient pool, and specific patient risk factors (pre-test
probabilities) and information about the diagnostic test
itself (the LR). The LR is used to assess how good a diag-
nostic test is and to help in selecting an appropriate diag-
nostic test(s) or sequence of tests. The LRs have
advantages over sensitivity and specificity because they are
less likely to change with the prevalence of the disorder,
they can be calculated for several levels of the symptom/
sign or test, they can be used to combine the results of
multiple diagnostic test and they can be used to calculate
the post-test probability for a target disorder. Post-test
probabilities can be calculated for different clinical sce-
narios or settings with various possible pre-test probabili-
ties (disease prevalence), using positive (LR+) and
negative (LR-) results for the interest tests.
Results
Adapted QUORUM statement checklist and flow diagram
of the study are included as an appendix [see Additional
File 3].
Literature search
The number of primarily found articles was 225. Two
hundred and two papers were excluded after abstract read-
ing because they were nor relevant to the study objective.
Twelve studies were excluded after reading them as full
papers, because they were not performed in children (8
studies) [19-26], did not use haemoglobin as reference
test (1) [27], did not assess individual signs of anaemia
(1) [28], did not present separately results for children (1)
[29], or did not perform clinical assessment of pallor (1)
[30]. Finally, eleven articles were included in the meta-
analysis [10,11,31-39].
All the studies we found had been performed in develop-
ing countries, mostly in children underfive. Eight were
performed in Africa[10,11,31,35-39], one in Paki-
stan[32], one in Bangladesh and Uganda [34] and one in
Brazil [33]. The Uganda component of one study was
excluded as it used packed red cells volume as gold stand-
ard [34].
Most studies reported their results using pre-specified
thresholds. All used one or more of the following haemo-
globin categories: <11 g/dL, <8 g/dL, 7 g/dL, and < 5 g/dL.
Only one study reported the results for 7 thresholds [36].
In this case, we re-constructed the results in the above
noted 4 categories to allow the comparison of results with
the other primary studies.
Table 1 summarizes main characteristics of primary stud-
ies, including the scores of methodological quality. There
were studies that evaluated more than one sub-group of
subjects and such results are shown separately.
Table 5: Pooled diagnostic performance markers at Hb <5 g/dL
Clinical 
Pallor
Total N Diseased Sensitivity 
(95% IC)
Specificity 
(95% IC)
Likelihood 
Ratio+(CI, 95%)
Likelihood 
Ratio-(CI, 95%)
DOR (CI, 
95%)
AUC* 
SROC**
Conjunctiva 12649 603 47.6(43.6–51.7) 88.1(87.5–88.7) 8.4(3.9–18.5) 0.6(0.5–0.7) 20.6(10.1–42.2) 0.8889
Palm 12780 603 56.6(52.5–60.5) 87.9(87.3–88.5) 7.7(3.1–19.0) 0.5(0.4–0.5) 21.6(10.5–44.4) 0.8922
Nailbed 10623 494 61.1(56.7–65.4) 87.7(87.1–88.4) 7.9(2.7–22.7) 0.4(0.4–0.5) 22.9(9.8–54.0) 0.8964
*AUC: area under the curve, **SROC: summary receiver operating characteristics curve.
Table 4: Pooled diagnostic performance markers at Hb <7 g/dL
Clinical 
Pallor
Total N Diseased Sensitivity 
(95% IC)
Specificity 
(95% IC)
Likelihood 
Ratio+(CI, 95%)
Likelihood 
Ratio-(CI, 95%)
DOR 
(CI, 95%)
AUC* 
SROC**
Conjunctiva 8693 428 36.9(32.5–41.6) 88.7(88–89.4) 4.5(1.9–1.1) 0.8(0.6–0.9) 6.6(2.6–17.2) 0.7821
Palm 8726 429 35.7(31.3–40.3) 89.2(88.5–89.8) 4.2(2.3–7.7) 0.7(0.6–0.9) 6.8(3.2–14.4) 0.7851
Nailbed 8716 428 32.2(28–36.8) 90.8(90.1–91.4) 5.8(2.2–15.2) 0.6(0.5–0.9) 10.3(2.7–39.1) 0.8297
*AUC: area under the curve, **SROC: summary receiver operating characteristics curveBMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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Homogeneity assessment
Chi-square test for proportions and Cochran Q for LR's
and DOR's showed heterogeneity for results of primary
studies within each threshold. For graphical display of the
heterogeneity, 95% CIs for DOR's of individual studies
are shown in Figure 1, 2, 3, 4.
Outliers at each haemoglobin category were identified
through the DOR's graphs. Point estimates with confi-
dence limits were plotted for each individual study. Those
studies or results whose DOR's graphs were outside the
95% bounds of the pooled DOR were considered outliers.
At haemoglobin <11 g/dL there was one outlier for palmar
pallor [38]. At haemoglobin <8 g/dL there were 2 outliers
for conjunctival pallor [10,37], one for nailbed [37], and
one for palmar pallor [37]. At haemoglobin <5 g/dL there
was 1 outlier for conjunctival pallor [39], 2 for palmar pal-
lor [10,39], and one for nailbed pallor [39].
Mathematical pooling
As diagnostic performance of primary tests showed heter-
ogeneity, mathematical pooling for them was calculated
using the DerSimonian Laird random effects model, to
incorporate variation among studies. With this method
the weighted average of LR's and DOR's logs are calcu-
lated. Tables 2, 3, 4, 5 show the pooled sensitivities, spe-
cificities, LR's, DOR's with their 95% CIs. Table 6 shows
the pooled LR's and DOR's after exclusion of outliers.
Pooled DOR at haemoglobin <11 g/dL was 4.3 (95% CI
2.6–7.2) for palmar pallor, 3.7 (2.3–5.9) for conjunctival
pallor, and 3.4 (1.8–6.3) for nailbed pallor. For the same
haemoglobin threshold, pooled LR+ was 3.0 (95% CI
2.0–4.6) for palmar pallor, 2.7 (1.6–4.5) for nailbed pal-
lor, 2.3 (1.7–3.1) for conjunctival pallor. Also for haemo-
globin <11 g/dL, pooled LR- was 0.7 (CI 95% 0.6–0.8) for
palmar pallor, 0.7 (0.5–0.9) for conjunctival pallor, and
0.8 (0.7–0.9) for nailbed pallor. DOR's and LR's were
slightly better for nailbed pallor at all other haemoglobin
thresholds. The pooled diagnostic parameters did not vary
substantially after excluding outliers, except that the mod-
est DOR superiority for palmar pallor at haemoglobin
<11 g/dL disappeared and improved over the other signs
at haemoglobin <5 g/dL (Table 6).
Exploration of heterogeneity
Method of haemoglobin measurement, type of examiner,
continent, clinical setting (outpatients or inpatients) and
quality score entered as covariates for most studies. Multi-
variate metaregression revealed that the only influential
covariates on LnDOR for palmar pallor were type of
observer (β = 3.16, p = 0.04; RDOR = 23.6, 95% CI =
1.05–531) and haemoglobin technique (β = -5.02, p =
0.03; RDOR = 0.01, 95% CI = 0.00–0.4) at haemoglobin
<8 g/dL. There was not any other covariate significantly
influencing on LnDOR for the other index clinical signs at
any other haemoglobin threshold.
Post-test probabilities of anaemia
Figures 5, 6, 7, 8 show the post-test probabilities for each
particular sign at different haemoglobin thresholds before
and after exclusion of outliers. Mild anaemia accounts for
the greatest burden of disease in the world. Thus, consid-
ering different possible settings according to anaemia
prevalence (pre-test probability), we illustrate here some
post-test probabilities for positive and negative results of
clinical signs of anaemia at haemoglobin <11 g/dL (Figure
5). For a clinical sign present and at 8% of anaemia prev-
alence, the post-test probability of disease increased to
21% for palmar pallor, to 19% for nailbed pallor, and to
17% for conjunctival pallor. For the same threshold and
at 50% of anemia prevalence, the post-test probability
increased to 75% for palmar pallor, to 73% for nailbed
pallor, and to 70% for conjunctival pallor. And at 80% of
anemia prevalence, the post-test probability of disease
increased to 92% for palmar and nailbed pallor, and to
90% for conjunctival pallor. Like for DOR's and LR's, the
discrete superiority of palmar pallor disappeared when
outliers were excluded (Figure 5). At the same haemo-
globin threshold (<11 g/dL), when a sign was absent, the
post-test probability decrease was modest for any of the
clinical signs of anaemia (Figure 5). The same trend was
Table 6: Pooled likelihood ratios and diagnostic odds ratios for index tests after excluding outliers
Hb <11 g/dL Hb <8 g/dL Hb <5 g/dL
Clinical pallor LR+ LR- DOR LR+ LR- DOR LR+ LR- DOR
Conjunctiva --- --- --- 2.6 0.4 6.4 7.1 0.5 19.7
--- --- --- (2.2 – 3.0) (0.2 – 0.7) (3.7 – 11.0) (2.8 – 17.6) (0.4 – 0.7) (11.5 – 33.5)
Palmar 2.6 0.8 3.5 2.7 0.3 8.3 6.9 0.5 23.8
(1.8 – 3.6) (0.7 – 0.8) (2.3 – 5.1) (2.2 – 3.2) (0.2 – 0.5) (5.5 – 12.7) (2.3 – 20.4) (0.4 – 0.6) (13.4 – 42.3)
Nailbed --- --- --- 3.1 0.3 9.3 5.6 0.4 16.6
--- --- --- (2.3 – 4.2) (0.2 – 0.6) (4.9 – 17.7) (2.1 – 15.3) (0.4 – 0.6) (7.7 – 35.9)
Numbers in parenthesis denote 95% CIs. Dotted lines (---) denote absence of outliers. Hb <7 g/dL did not have outliers.BMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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observed at other haemoglobin thresholds (Figures 6, 7,
8). Again, the exclusion of outliers did not change sub-
stantially the post-test probabilities.
Discussion
We did not find a highly accurate clinical sign for diagnos-
ing anaemia. Palmar pallor was modestly superior at hae-
moglobin less than 11 g/dL and nailbed was slightly
superior at all other haemoglobin thresholds. After exclu-
sion of outliers, nailbed pallor performed slightly better
than the other signs, except at haemoglobin less than 5 g/
dL, where palmar pallor improved somewhat over con-
junctival and nailbed pallor.
Sensitivity of clinical signs ranged widely from 29.2%
through 80.9% at different haemoglobin thresholds. Only
palmar pallor showed 80.9% of sensitivity at haemo-
Post-test probabilities for positive and negative results of  clinical signs of anaemia for different pre-test probabilities, at  Hb<8 g/dL, with and without outliers Figure 6
Post-test probabilities for positive and negative results of 
clinical signs of anaemia for different pre-test probabilities, at 
Hb<8 g/dL, with and without outliers.
Post-test probabilities of positive and negative results of clin- ical signs of anaemia for different pre-test probabilities, at  Hb<11 g/dL, with and without outliers Figure 5
Post-test probabilities of positive and negative results of clin-
ical signs of anaemia for different pre-test probabilities, at 
Hb<11 g/dL, with and without outliers.BMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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globin less than 8 g/dL. And only nailbed pallor reached a
90.8% of specificity at haemoglobin less than 7 g/dL. This
means that the rates of false positive and false negative
results are unacceptably high for the clinical diagnosis of
anaemia. The prevalence of asymptomatic anaemia in
children may be as high as 87% in some areas of the world
such south-eastern Tanzania [40]. Iron supplementation
for all children in such a setting with a silent burden of
anaemia has been suggested as a control strategy [40].
This can be associated with periodical deworming in trop-
ical and subtropical countries [41].
A technical document supporting the use of palmar pallor
as part of IMCI guidelines states that for detection of
severe anaemia clinical signs should be as sensitive and
specific as possible, to avoid missing referral for a poten-
tially life-saving blood transfusion, and to avoid unneces-
sary referrals which would burden the families and the
health facilities [8]. We did not find high values of sensi-
tivity and specificity for any of the clinical signs of anae-
mia. Palmar pallor, the recommended sign, did not
perform particularly better. The pooled sensitivities are
higher and the pooled specificities lower than those for
more severe anaemia. This is due to the fact that different
studies did not assess necessarily the same haemoglobin
cut-offs, which is shown in Table 1. By contrast, the diag-
nostic odds ratio, which constitutes a single test perform-
ance indicator, increases at lower haemoglobin cut-off
values. This is one of the reasons we chose to include
DOR's as another summary statistics for pooling accuracy
of clinical signs in our study. In addition, DOR offers the
advantage of overcoming the under-estimation of diag-
nostic accuracy that often occurs if one pools the results of
primary studies just in terms of sensitivity and specificity.
Post-test probabilities of positive and negative results of clin- ical signs of anaemia for different pre-test probabilities, at  Hb<5 g/dL, with and without outliers Figure 8
Post-test probabilities of positive and negative results of clin-
ical signs of anaemia for different pre-test probabilities, at 
Hb<5 g/dL, with and without outliers.
Post-test probabilities of positive and negative results of clin- ical signs of anaemia for different pre-test probabilities, at  Hb<7 g/dL (no outliers were found) Figure 7
Post-test probabilities of positive and negative results of clin-
ical signs of anaemia for different pre-test probabilities, at 
Hb<7 g/dL (no outliers were found).BMC Pediatrics 2005, 5:46 http://www.biomedcentral.com/1471-2431/5/46
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We further explored whether the post-test probabilities of
anaemia changed substantially when clinical signs were
present or absent for different prevalences of the condi-
tion (pre-test probabilities). Pre-test probabilities of 50%
and 8% represent the anaemia prevalence of Peru and
Chile, respectively [4,5], and 80% is close to prevalence
recently reported in southern Tanzania [40]. At haemo-
globin less than 11 g/dL, post-test probabilities of anae-
mia did not show a substantial change in presence or
absence of clinical signs, except in a scenario with 8% of
prevalence. On an individual basis, a good clinical sign
would lead correctly, when present, to prescribe iron and
conversely, when absent, to withhold it. On the other
side, an accurate diagnosis of severe anaemia should lead
to a prompt referral for blood transfusion and additional
interventions depending on the underlying causes of
anaemia. However, at haemoglobin less than 5 g/dL, post-
test probabilities of disease when a clinical sign was
present increased up to 5 times only in a scenario with 8%
of anaemia prevalence, but less than the double in scenar-
ios with 50% and 80% of prevalence. The post-test prob-
abilities decreased only slightly when a clinic sign was
absent, at both haemoglobin less than 11 and 5 g/dL, irre-
spective of anaemia prevalence. Thus, this meta-analysis
does not support the recommendation of taking a man-
agement decision on the basis of presence or absence of
any of the clinical signs of anaemia assessed.
There are some limitations of primary studies included
that may have influenced on the results of the meta-anal-
ysis. First, most studies did not assess inter-observer varia-
tion. Due to the subjective component in the appreciation
of clinical pallor, it is important to quantify this factor.
Second, most studies were performed in Africa, limiting
their generalizability to other regions of the world due to
phenotypic differences, varying anaemia prevalence and
different causes such as malaria and intestinal parasitosis.
For instance, it has been documented that a greater pal-
mar pigmentation in Bangladesh was associated with a
decreased sensitivity of palmar pallor [34]. In addition,
high rates of blepharoconjunctivitis may obscure con-
junctival pallor and also decrease its sensitivity [42].
Third, the diagnostic accuracy of combined signs was
rarely performed [32,34]. Combining signs may increase
the performance of clinical signs, even if such an evalua-
tion may also increase in complexity. Trade-offs between
combination of clinical signs and complexity of evalua-
tion should be considered if combined signs display bet-
ter diagnostic accuracy.
Conclusion
We did not find a highly accurate clinical sign of anaemia.
In view of poor performance of clinical signs, universal
iron supplementation of children may be an adequate
control strategy at public health level, particularly in high
prevalence areas, as was recently suggested [40]. Further
well-designed studies are needed for settings other than
Africa.
They should assess inter-observer variation, performance
of combined clinical signs, phenotypic differences and
different degrees of anaemia.
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